Together with Leyden Labs, we (Hillmark & Leyden Labs) aim to go beyond traditional antiviral drugs. We are ambitiously determined to develop novel pan-antiviral drugs to prepare us and help people to fight against the next unexpected pandemic.

 

Beukenhorst AL et al., The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection. Front. Virol. 2023, 3:1130102.